Image
g

Translating Scientific Discoveries into Patient Therapies

One of only a select number of programs worldwide to serve as a Clinical Center for TrialNet, a National Institutes of Health and JDRF sponsored research consortium charged with developing preventive therapies for diabetes, our team of experts conceptualize, design, and execute trials related to all aspects of type 1 diabetes.

For more information on participating in a clinical trial, call 844-813-8273 (844-T1D-UCSF) or contact us below.

 

Online Screener

 

Email Us

 

 

Current Studies

TrialNet Pathway to Prevention Study: for Family Members of relatives with Type 1

  • Ages 2 ½ - 45: 1st degree relatives 2 ½ - 45, 2nd and 3rd degree relatives 2 ½ - 20
  • Initial screening for type 1 diabetes antibodies
  • Participants who are antibody positive can participate in monitoring, and may be eligible for prevention studies

 

Hydroxychloroquine Prevention Study: HCQ for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus

  • Ages 3 and up
  • For people with 2 or more antibodies and normal glucose tolerance, determined by participating in TrialNet screening and monitoring
  • Oral medication taken at home
  • 2:1 Treatment/Placebo

 

PROTECT: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

  • 8-17 yr olds
  • 12 consecutive days of Teplizumab infusions at Baseline and again at 6 months
  • Baseline first infusion within 42 days of diagnosis
  • 2:1 Treatment/Placebo

 

TOPPLE T1D: A multiple ascending dose trial investigating safety, tolerability and pharmacokinetics of NNC0361-0041 administered subcutaneously to patients with type 1 diabetes mellitus

  • Phase I Study for adults 18-45
  • Recombinant supercoiled plasmid encoding four human proteins: (preproinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2)
  • 4 Cohorts, with increasing dosage
  • 3:1 Treatment/Placebo
  • Weekly subcutaneous injections for 12 weeks
  • 48 hr inpatient stay for first dose, all other visits are outpatient